Bruker (NASDAQ:BRKR) Releases FY22 Earnings Guidance

Bruker (NASDAQ:BRKRGet Rating) updated its FY22 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $2.29 to $2.33 for the period, compared to the consensus estimate of $2.29. The company issued revenue guidance of $2.539 billion to $2.587 billion, compared to the consensus revenue estimate of $2.56 billion.

Several equities research analysts have weighed in on the stock. The Goldman Sachs Group lowered their target price on shares of Bruker from $73.00 to $60.00 and set a sell rating for the company in a research note on Wednesday, April 13th. StockNews.com started coverage on shares of Bruker in a research note on Thursday, March 31st. They set a buy rating for the company. Zacks Investment Research downgraded shares of Bruker from a buy rating to a hold rating and set a $64.00 price objective for the company. in a research note on Tuesday, April 19th. Finally, SVB Leerink lifted their price objective on shares of Bruker from $84.00 to $85.00 and gave the stock an outperform rating in a research note on Monday, February 14th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of Hold and an average price target of $77.00.

Bruker stock traded down $3.12 during mid-day trading on Thursday, hitting $60.73. The company had a trading volume of 28,245 shares, compared to its average volume of 731,149. The company has a market capitalization of $9.07 billion, a price-to-earnings ratio of 35.08, a P/E/G ratio of 1.36 and a beta of 1.26. Bruker has a 12-month low of $56.35 and a 12-month high of $92.35. The company’s fifty day moving average is $64.14 and its 200-day moving average is $71.97. The company has a current ratio of 2.63, a quick ratio of 1.88 and a debt-to-equity ratio of 1.13.

Bruker (NASDAQ:BRKRGet Rating) last announced its quarterly earnings results on Wednesday, May 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.07. Bruker had a net margin of 11.46% and a return on equity of 30.77%. The firm had revenue of $595.00 million for the quarter, compared to the consensus estimate of $572.50 million. During the same period in the prior year, the firm posted $0.44 earnings per share. The firm’s quarterly revenue was up 7.3% compared to the same quarter last year. As a group, sell-side analysts expect that Bruker will post 2.31 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, March 18th. Investors of record on Tuesday, March 1st were issued a $0.05 dividend. This is a boost from Bruker’s previous quarterly dividend of $0.04. The ex-dividend date of this dividend was Monday, February 28th. This represents a $0.20 dividend on an annualized basis and a yield of 0.33%. Bruker’s dividend payout ratio is presently 10.99%.

Institutional investors have recently bought and sold shares of the company. JustInvest LLC raised its position in shares of Bruker by 96.1% during the 4th quarter. JustInvest LLC now owns 6,716 shares of the medical research company’s stock worth $564,000 after purchasing an additional 3,292 shares during the last quarter. BlackRock Inc. lifted its position in shares of Bruker by 66.7% in the fourth quarter. BlackRock Inc. now owns 10,844,554 shares of the medical research company’s stock valued at $909,967,000 after acquiring an additional 4,337,595 shares in the last quarter. Comerica Bank purchased a new position in shares of Bruker in the fourth quarter valued at approximately $3,146,000. NewEdge Advisors LLC boosted its stake in shares of Bruker by 17.4% in the fourth quarter. NewEdge Advisors LLC now owns 26,287 shares of the medical research company’s stock worth $2,206,000 after acquiring an additional 3,898 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in shares of Bruker by 3,479.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 115,616 shares of the medical research company’s stock worth $9,757,000 after purchasing an additional 112,386 shares in the last quarter. Institutional investors and hedge funds own 76.09% of the company’s stock.

About Bruker (Get Rating)

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies.

Featured Stories

Earnings History and Estimates for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.